Exelixis, Inc.: Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening

Related Keywords

Hal Mackins ,Martin Welschof ,Cecilia Hofvander ,Varant Shirvanian ,Peter Lamb ,Daiichi Sankyo Company ,Twitter ,Bioinvent International ,Genentech Inc ,Bioinvent International Ab Nasdaq Stockholm ,Nasdaq ,Exchange Commission ,Exelixis Inc ,Facebook ,Nasdaq Stockholm ,Executive Vice President ,Scientific Strategy ,Chief Scientific Officer ,Standard Poor ,Exelixi Quarterly Report ,Investors Contact ,Investor Relations ,Media Contact ,Invent Investors Media Contact ,Exelixis ,Bioinvent ,Stablish ,Exclusive ,Option ,License ,Agreement ,Evelop ,Novel ,Ntibody ,Ased ,Immuno ,Ncology ,Therapies ,